SCLC has various subtypes defined by differential expression of ASCL1, NEUROD1 & POU2F3 (SCLC-A, -N, & -P). A new PLCG2-high SCLC phenotype with poor survival appears to be profibrotic & associated with immunosuppressive monocyte/macrophages.https://t.co/nJGr0oPSMM pic.twitter.com/pLt564QcO7

— soria (@jsoriamd) October 18, 2021

Novel targeted therapies like enasidenib (IDH2 inhibitor) added to standards of care are improving #AML outcomeshttps://t.co/Y7BlovT8IC via @TheLancetOncol |
Courtney D DiNardo, MD, H M Kantarjian, MD, of @MDAndersonNews #Leukemia
#leusm pic.twitter.com/O0nJY94pn8

— Hagop Kantarjian,MD (@DrHKantarjian) October 19, 2021

This! ~40 new drugs/indications by @FDAOncology in 2021. Imperative for gen oncologists to stay on top + partner w/ tertiary centers. So🙏🏽for discussions here by #MedTwitter @OncoAlert #OncMed @CharuAggarwalMD @DrSGraff @JAMouabbi @PTarantinoMD @pashtoonkasi @DrNeilLove @OncLive https://t.co/6oKvDfnxNM

— Oncology Brothers (@OncBrothers) October 21, 2021

Outstanding study led by @AmericanCancer research team shows how smoking cessation reduces excess cancer mortality risk from continued smoking. Need more efforts to discourage initiation and promote cessation! #EndNicotineAddiction https://t.co/jHMVC7NCLr

— Bill Cance (@AmerCancerCMSO) October 21, 2021

Absolutely, COVID hasn’t stopped cancer. Now is definitely the time to get back on track with regular mammograms and other cancer screening. #getscreened https://t.co/B8TpLjCMKY

— Laura Makaroff (@lauramakaroff) October 22, 2021